Search results
injection 25 to 50 mg 90 or 120 mg, based on the oral dose Maintenance dose 300 to 400 mg 441 to 1,064 mg 150 to 405 mga 39 to 234 mg 273 to 819 mg 25 to 50 mg 90 or 120 mg Maintenance dose frequency Every 4 weeks 441 mg: every 4 weeks 662 mg: every 4 weeks 882 mg: every 4 or 6 weeks 1,064 mg: every 8 weeks
Show details. Contents. Table 1 Cost Comparison Table of Antipsychotic Drugs for Schizophrenia. cap = capsule; IM = intramuscular; mg = milligrams; ODT = oral disintegrating tablet; tab = tablet; XR = extended release.
Pharmacoeconomic Review Report: Buprenorphine extended-release injection (Sublocade): (Indivior Canada, Ltd.): Indication: For the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product [Internet].
14 maj 2024 · Kishimoto T, Hagi K, Kurokawa S, et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies.
26 lut 2022 · We did a systematic review and network meta-analysis comprising 127 RCTs of 18 152 individuals with stabilised symptoms of schizophrenia or schizoaffective disorder and compared 32 oral and long-acting injectable antipsychotics for 14 different efficacy and tolerability outcomes.
This report describes how price indices are used to compare prescription drug prices between countries, summarizes findings related to international prescription drug price comparisons presented in prior studies, and presents new price comparisons that are based on 2018 data.
Comparison of Buprenorphine (BUP) Long-Acting Subcutaneous Injections. Monthly Sublocade®. Weekly & monthly Brixadi®. Indication. Treatment of moderate to severe opioid use disorder (OUD) among patients tolerating transmucosal buprenorphine containing product for at least 1 week.
